Literature DB >> 21371511

Induced pluripotent stem cells for regenerative cardiovascular therapies and biomedical discovery.

Ali Nsair1, W Robb MacLellan.   

Abstract

The discovery of induced pluripotent stem cells (iPSC) has, in the short time since their discovery, revolutionized the field of stem cell biology. This technology allows the generation of a virtually unlimited supply of cells with pluripotent potential similar to that of embryonic stem cells (ESC). However, in contrast to ESC, iPSC are not subject to the same ethical concerns and can be easily generated from living individuals. For the first time, patient-specific iPSC can be generated and offer a supply of genetically identical cells that can be differentiated into all somatic cell types for potential use in regenerative therapies or drug screening and testing. As the techniques for generation of iPSC lines are constantly evolving, new uses for human iPSC are emerging from in-vitro disease modeling to high throughput drug discovery and screening. This technology promises to revolutionize the field of medicine and offers new hope for understanding and treatment of numerous diseases.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21371511      PMCID: PMC3109180          DOI: 10.1016/j.addr.2011.01.013

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  60 in total

1.  Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells.

Authors:  Timothy J Nelson; Almudena Martinez-Fernandez; Satsuki Yamada; Carmen Perez-Terzic; Yasuhiro Ikeda; Andre Terzic
Journal:  Circulation       Date:  2009-07-20       Impact factor: 29.690

2.  Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs.

Authors:  Tomomi G Otsuji; Itsunari Minami; Yuko Kurose; Kaori Yamauchi; Masako Tada; Norio Nakatsuji
Journal:  Stem Cell Res       Date:  2010-02-06       Impact factor: 2.020

3.  Stem cells and ethics: current issues.

Authors:  Jennifer Blair McCormick; Holly A Huso
Journal:  J Cardiovasc Transl Res       Date:  2009-12-01       Impact factor: 4.132

4.  Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts.

Authors:  A E Schnieke; A J Kind; W A Ritchie; K Mycock; A R Scott; M Ritchie; I Wilmut; A Colman; K H Campbell
Journal:  Science       Date:  1997-12-19       Impact factor: 47.728

5.  Variation in the safety of induced pluripotent stem cell lines.

Authors:  Kyoko Miura; Yohei Okada; Takashi Aoi; Aki Okada; Kazutoshi Takahashi; Keisuke Okita; Masato Nakagawa; Michiyo Koyanagi; Koji Tanabe; Mari Ohnuki; Daisuke Ogawa; Eiji Ikeda; Hideyuki Okano; Shinya Yamanaka
Journal:  Nat Biotechnol       Date:  2009-07-09       Impact factor: 54.908

6.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

7.  Induced pluripotent stem cells from a spinal muscular atrophy patient.

Authors:  Allison D Ebert; Junying Yu; Ferrill F Rose; Virginia B Mattis; Christian L Lorson; James A Thomson; Clive N Svendsen
Journal:  Nature       Date:  2008-12-21       Impact factor: 49.962

8.  Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin.

Authors:  Jacob Hanna; Marius Wernig; Styliani Markoulaki; Chiao-Wang Sun; Alexander Meissner; John P Cassady; Caroline Beard; Tobias Brambrink; Li-Chen Wu; Tim M Townes; Rudolf Jaenisch
Journal:  Science       Date:  2007-12-06       Impact factor: 47.728

9.  Generation of germline-competent induced pluripotent stem cells.

Authors:  Keisuke Okita; Tomoko Ichisaka; Shinya Yamanaka
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

10.  Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages.

Authors:  S I Nishikawa; S Nishikawa; M Hirashima; N Matsuyoshi; H Kodama
Journal:  Development       Date:  1998-05       Impact factor: 6.868

View more
  8 in total

1.  Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells.

Authors:  Nan Cao; Zumei Liu; Zhongyan Chen; Jia Wang; Taotao Chen; Xiaoyang Zhao; Yu Ma; Lianju Qin; Jiuhong Kang; Bin Wei; Liu Wang; Ying Jin; Huang-Tian Yang
Journal:  Cell Res       Date:  2011-12-06       Impact factor: 25.617

Review 2.  Diabetes mellitus and cellular replacement therapy: Expected clinical potential and perspectives.

Authors:  Alexander E Berezin
Journal:  World J Diabetes       Date:  2014-12-15

Review 3.  Induced pluripotent stem cells as a disease modeling and drug screening platform.

Authors:  Antje D Ebert; Ping Liang; Joseph C Wu
Journal:  J Cardiovasc Pharmacol       Date:  2012-10       Impact factor: 3.105

4.  A combined hiPSC-derived endothelial cell and in vitro microfluidic platform for assessing biomaterial-based angiogenesis.

Authors:  Sylvia L Natividad-Diaz; Shane Browne; Amit K Jha; Zhen Ma; Samir Hossainy; Yosuke K Kurokawa; Steven C George; Kevin E Healy
Journal:  Biomaterials       Date:  2018-11-28       Impact factor: 12.479

Review 5.  Cardiomyocytes derived from human induced pluripotent stem cells as models for normal and diseased cardiac electrophysiology and contractility.

Authors:  Adriana Blazeski; Renjun Zhu; David W Hunter; Seth H Weinberg; Elias T Zambidis; Leslie Tung
Journal:  Prog Biophys Mol Biol       Date:  2012-08-07       Impact factor: 3.667

Review 6.  Perspectives of induced pluripotent stem cells for cardiovascular system regeneration.

Authors:  Mária Csöbönyeiová; Štefan Polák; L'uboš Danišovič
Journal:  Exp Biol Med (Maywood)       Date:  2015-01-16

7.  Physical stimulation by REAC and BMP4/WNT-1 inhibitor synergistically enhance cardiogenic commitment in iPSCs.

Authors:  Valentina Basoli; Sara Santaniello; Salvatore Rinaldi; Vania Fontani; Gianfranco Pigliaru; Matthias Wieser; Agata Strajeriu; Alessandro Castagna; Heinz Redl; Carlo Ventura; Regina Grillari; Margherita Maioli
Journal:  PLoS One       Date:  2019-01-23       Impact factor: 3.240

8.  Developing microRNA screening as a functional genomics tool for disease research.

Authors:  Derek Lemons; Mano R Maurya; Shankar Subramaniam; Mark Mercola
Journal:  Front Physiol       Date:  2013-08-27       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.